Invasive aspergillosis (IA) in liver transplant recipients is associated with poor response rates and a very high mortality rate, despite administration of therapy with conventional amphotericin B. We conducted a singlecenter, retrospective study to compare the outcome of liver transplant recipients with IA who received amphotericin B lipid complex (ABLC) or conventional amphotericin B. IA was present in 12 ABLC-treated patients (definite, 4; probable, 8) and 29 amphotericin B recipients (definite, 11; probable, 18) in the historical cohort. The 60-day mortality rate was lower in the ABLC cohort: 4 (33%) of 12 patients versus 24 (83%) of 29 patients ( ). Only 1 of 4 ABLC recipients with definite IA died, compared with all 11 in the amphotericin B P p .006 group. Sixty-day survival probability curves was significantly lower in the amphotericin B cohort ( ). P p .008 ABLC therapy was the only independent mortality-protective variable (odds ratio, 0.31; 95% confidence interval, 0.07-0.44; ). First-line or early salvage therapy for IA with ABLC was associated with significantly P p .02 improved survival relative to a comparable historical group treated with amphotericin B.
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Invasive aspergillosis (IA) after liver transplantation has been associated with devastatingly high mortality rates, with pooled mortality rates among liver transplant recipients of 88% during 1972-1995 [1] and 67.6% during 1995-1999; [2] several case series have reported mortalities of 92%-100% [3] [4] [5] . High-dose amphotericin B (р1.0 mg/kg q.d.) has remained the traditional first line of chemotherapy in conjunction with judicious tapering of immunosuppressive therapy. Surgical re-section of isolated lesions may be curative, but only in select cases [6] [7] [8] [9] . Favorable outcomes have been described with oral itraconazole; however, this experience has been limited to single case reports or small case series [10, 11] .
Amphotericin B lipid complex (ABLC; Abelcet; Elan Pharmaceuticals) is a 1:1 molar combination of amphotericin B with 2 lipid compounds (dimyristoyl phosphatidyl choline and dimyristoyl phosphatidyl glycerol) to form a ribbon-like structure [12] . This agent has been approved for the treatment of multiple mycoses, including those due to Aspergillus species, that are refractory to amphotericin B therapy or that occur in amphotericin B-intolerant patients [13] . On the basis of our poor outcomes with amphotericin B in treating liver transplant recipients with aspergillosis, ABLC became the "local first line of therapy" in February 1996. Thus, we compared the outcomes for liver trans-plant recipients who had IA treated with ABLC with those in an historical cohort receiving amphotericin B.
MATERIALS AND METHODS

Study populations.
The ABLC cohort consisted of liver transplant recipients who had IA diagnosed during the period of February 1996 (when ABLC became available at our health care center) through February 2001. The amphotericin B cohort was retrospectively derived by a query of the computerized microbiological archive for all liver transplant recipients from whom Aspergillus species had been isolated during the period of January 1992 through January 1996. Inclusion required evidence of symptomatic infection and radiographic changes compatible with pulmonary aspergillosis or disease at extrapulmonary sites. Patients were excluded from either study cohort if they did not exhibit compatible evidence of aspergillosis or if they received treatment for !3 days.
Peritransplantation management protocol. All liver transplantations were done in orthotopic fashion, with or without extracorporeal venovenous bypass. Posttransplantation immunosuppressive therapy consisted of methylprednisolone and FK-506 (Tacrolimus; Fujisawa). Allograft rejection was usually treated with a 1-g intravenous methylprednisolone bolus, with or without a 5-day recycle of methylprednisolone. Steroidrefractory rejection was managed with a 7-10-day course of monoclonal antilymphocyte therapy (OKT3; Orthoclone; Roche). Anti-infective prophylaxis included wound prophylaxis with intravenous ampicillin and cefotaxime or ampicillin-sulbactam for 48-72 h, enteral mycostatin treatment, prophylaxis for herpes simplex virus infection with oral acyclovir, and oral trimethoprim-sulfamethoxazole for prevention of Pneumocystis carinii pneumonia. Patients deemed to be at high risk for early fungal infection received either "low-dose" amphotericin B (10-20 mg q.d. for 7-14 days) or fluconazole (200-400 mg q.d.). Cytomegalovirus (CMV) infection surveillance included weekly shell vial centrifugation with blood, throat, and urine specimens during most of the historical control period. During the latter part of the historical period and the entire ABLC period, CMV surveillance was done by weekly quantitative leukocyte CMV antigenemia measurement. Parenteral ganciclovir was used for prophylaxis for some high-risk recipients (CMVseropositive donor to a CMV-seronegative recipient and recipients of prior OKT3 therapy), and it was used preemptively for patients with significant levels of CMV antigenemia.
Study patient database. All data on demographic characteristics, quantity of immunosuppression, and all serious infectious complications were recorded. Aspergillus-related data included the date and site of isolation, species of Aspergillus, attributable signs or symptoms, results of pertinent radiographic tests, and daily and cumulative dose and duration of 2 methods. Student's t test was used to compare the sample means of continuous variable data. Kaplan-Meier 60-day survival probability curves were compared using log rank methods. Logistic regression modeling was used to assess multiple baseline and during-therapy variables for mortality association. The 2-tailed significance level was . a ! .05
RESULTS
Comparison of study cohorts at baseline. Fourteen ABLCtreated patients and 34 amphotericin B-treated patients were identified. Two ABLC-treated patients and 5 amphotericin B-treated patients were excluded because of inadequate duration of treatment. There were 34 cases of IA among 924 liver transplant recipients (incidence, 3.6%) during the amphotericin B period and 14 cases among 715 liver transplant recipients (incidence, 1.9%) during the ABLC period. The higher incidence during the amphotericin B period was in part due to an outbreak in July-August 1994, when 8 cases related to in-hospital air contamination occurred. Among the 12 eligible ABLCtreated patients, 4 had definite IA and 8 met criteria for probable IA. Among 29 eligible amphotericin B-treated patients, there were 11 definite and 18 probable cases of IA. Demographic and clinical variables at the time of diagnosis are summarized in table 1. The vast majority of patients in both groups were critically ill and in the intensive care unit. The dominant comorbidities in both groups were shock and respiratory and renal failure; however, no significant differences in the type and number of coexisting organ failure(s) were observed. The median time from the day of the first liver transplantation to diagnosis was longer in the ABLC group (61 vs. 52 days). Notably, 3 patients in each cohort received a diagnosis 11 year after the liver transplantation; for the ABLC group, the diagnoses were made on posttransplantation days 1795, 2340, and 2435; and for the amphotericin B group, they were made on posttransplantation days 540, 892, and 1275).
Pulmonary disease was the definite or probable primary site of IA in the majority of patients in both groups (table 2). The most common presenting radiographic changes included solitary or multiple pulmonary nodules, focal alveolar infiltrates, or diffuse infiltrates. The index positive respiratory culture was of sputum or an endotracheal or tracheostomy aspirate obtained from 7 ABLC-treated patients and 16 amphotericin B-treated patients or of bronchoalveolar lavage fluid obtained . Of the patients who had an additional respiratory specimen available before the initiation of antifungal therapy, 5 (62%) of 8 ABLC-treated patients and 10 (77%) of 13 amphotericin B-treated patients still had Aspergillus isolated from the same site. Documented or suspected extrapulmonary disease was present in a minority of patients before treatment (ABLC group, 3 patients; amphotericin B group, 6 patients). The most common extrapulmonary focus in both cohorts was the intra-abdominal cavity (ABLC group, 2 patients; amphotericin B group, 4 patients), of which either the peritoneal surface or fluid aspirated during exploratory laparotomy demonstrated evidence of aspergillosis on silver stains and culture. Other extrapulmonary sites included the CNS (amphotericin B group, 2 patients), skin (amphotericin B group, 1 patient) and surgical wound (ABLC group, 1 patient; amphotericin B group, 1 patient).
Treatment of aspergillosis. The median time delay from the first culture positive for Aspergillus species to the initiation of antifungal therapy was 3.5 days (range, 2-8 days) for ABLCtreated patients and 4.0 days (range, 2-9 days) for amphotericin B-treated patients (table 3) . Three ABLC-treated patients received amphotericin B treatment for only a short time (2, 4, and 5 days) before isolation of Aspergillus species. Patients in the ABLC group received an average daily ABLC dose of 5.2 mg/kg, whereas the average daily dose of amphotericin B in the amphotericin B group was 1.1 mg/kg. Daily ABLC doses of 15 mg/kg were used for part of the treatment duration for 3 ABLC-treated patients and 11 mg/kg for 5 amphotericin B-treated patients. Concurrent or sequential oral itraconazole was administered to both groups. Itraconazole use increased over the study time period: 8 (27%) of 29 amphotericin B-treated patients received concurrent itraconazole during part or all of the treatment period, compared with 9 (75%) of 12 ABLC-treated patients (
). Three ABLC-treated patients P p .01 and 2 amphotericin B-treated patients received itraconazole only after completion of ABLC or amphotericin B treatment. Itraconazole was prescribed at the time of hospital discharge for 5 ABLC-treated patients. Surgical excision of isolated lesions was rarely used in either group and included removal of a single right-upper lobe lung cavitary abscess for 2 ABLC-treated patients and removal of similar pulmonary lesions for 3 amphotericin B-treated patients. 
Management of immunosuppression after IA diagnosis.
Iatrogenic immunosuppression was completely withdrawn for 3 ABLC-treated patients (median, 5.5 days after diagnosis) and 8 amphotericin B-treated patients (median, 7 days after diagnosis). Enhanced immunosuppression (corticosteroid bolus/ recycle and/or antilymphocyte therapy) was administered for biopsy-documented or suspected breakthrough allograft rejection in a small number of cases in each treatment group.
Outcome of IA. The mortality rates for both cohorts and both definite and probable case subsets are separately displayed in ). When only deaths associated with IA were con-P p .006 sidered, a significant reduction in mortality was still observed in the ABLC cohort: 3 (25%) of 12 versus 22 (76%) of 29 ( ). Survival probability curves (figure 1) were signif-P p .007 icantly lower for the amphotericin B cohort during the entire 60-day period (
, by log rank test) . P p .008 One death in the ABLC-treated group with probable IA and 2 deaths in the amphotericin B-treated group with probable IA were unrelated to Aspergillus infection and were due to liver allograft failure with concurrent overwhelming bacterial sepsis. There were no survivors among all 11 patients with definite IA in the amphotericin B group. Six of these patients had available autopsy information: all demonstrated histological evidence of pulmonary aspergillosis, whereas extrapulmonary disease was present in 5 cases. No autopsy was done for the single ABLCtreated patient with definite IA who died; however, this death was still considered to be associated with IA. Logistic regression modeling was done to assess the independent association of multiple baseline variables (age of 150 years, multiple transplantations, extrapulmonary disease, mechanical ventilation, shock, artificial kidney support, liver allograft failure, and definite IA) and during-treatment variables (ABLC or amphotericin B treatment, itraconazole therapy, treatment of rejection with either corticosteroids or OKT3, repetitive Aspergillus isolation) with 60-day mortality (table 5) . Treatment with ABLC (OR, 0.31; 95% CI, 0.07-0.44;
) was the only significant P p .02 independent variable that conferred mortality protection. Paradoxically, antirejection therapy with either corticosteroids or OKT3 (OR , 0.01; 95% CI, 0.00-1.28; ) had borderline P p .06 mortality protection; however, the longer survival duration for such patients probably allowed them to manifest rejection to require therapy.
DISCUSSION
A number of factors have contributed to the high refractory lethality of IA in the liver transplant recipient. Aspergillosis is highly selective for liver transplant recipients with serious comorbidities (e.g., renal failure and liver allograft dysfunction) [5, [14] [15] [16] [17] and a higher aggregate burden of iatrogenic or CMVamplified immunosuppression, although the effect of the latter appears to be diminishing with effective antiviral strategies [18] .
There are inherent difficulties in establishing an early diagnosis of IA, including its overall low and sporadic incidence, nonspecific clinical presentation, and the modest sensitivity of culture of respiratory samples in detecting Aspergillus species [16, 19, 20] . Catastrophic de novo presentations (e.g., CNS hemorrhage) preclude the chance for an earlier diagnosis and effective therapy [21, 22] . In contrast to the neutropenic patient, for whom empirical amphotericin B therapy is closely linked to the severity and duration of neutropenia, which may effectively suppress incipient IA, there is no established "signal" in the liver transplant recipient to prompt empirical therapy. A favorable clinical response is observed only in the minority of cases, even with appropriate high-dose amphotericin B (11.0 mg/kg q.d.) [1, 2, 23] . Finally, the optimal cumulative amphotericin B dose and benefits of concurrent triazole and immunomodulating therapies remains unestablished.
Our study describes 2 significantly different outcome patterns over 2 consecutive treatment time periods: a 4-year historical period (January 1992 to January 1996) when amphotericin B was the standard approach for IA, followed by a 5-year Figure 1 . Kaplan-Meier survival probability curves and 95% CIs from first day of antifungal therapy to day 60 for combined (definite and probable invasive aspergillosis) cases treated with amphotericin B lipid complex (ABLC) or conventional amphotericin B (AmB). Probability of survival was significantly higher in the ABLC group ( , by the log rank test). P p .008 Table 5 . Multivariate analysis (binary logistic regression) for independent association of baseline and during-treatment variables with 60-day mortality. period (February 1996 to February 2001) when ABLC was prescribed as first-line or very early second-line therapy. Crude and IA-associated mortality in the combined definite and probable IA groups was significantly reduced in the ABLC cohort. There were no survivors among those with a definite IA diagnosis during the entire amphotericin B period. All 11 patient deaths in this group met the definition for IA-associated mortality, with death ensuing relatively rapidly, at a median of 16 days after the start of therapy (range, 4-48 days). Evidence of persistent pulmonary or disseminated disease was present in all 6 patients who underwent autopsy. In contrast, 3 of 4 patients treated with ABLC for definite IA survived to hospital discharge. Our definition of probable IA required both the presence of compatible clinical and radiographic signs and an Aspergillus isolate and is comparable with definitions used in other observational and prospective interventional studies [2, 5, [24] [25] [26] [27] . The positive predictive value of an Aspergillus isolate recovered from respiratory samples for IA is imprecise but is chiefly dependent on the host's category. Aspergillus isolation among bone marrow transplant recipients and patients with neutropenia is highly predictive (190%) of IA [28] [29] [30] . In contrast, the presence of an Aspergillus isolate in respiratory samples obtained from liver transplant recipients carries an intermediate to high positive predictive value [19, 31, 32] . Repetitive Aspergillus isolation and higher-density growth on culture have also been cited as discriminators that correlated with clinical significance [31] . A less prominent survival benefit was also observed among the cases of probable IA treated with ABLC versus amphotericin B: 2 of 8 versus 11 of 18 ( ). Com-P p .20 parison of mortality rates between patients with definite and probable IA within each treatment group revealed equivalent outcomes (1 of 4 patients vs. 2 of 8 patients) in the ABLC group but lower mortality in the amphotericin B-treated group with probable IA (11 of 11 patients vs. 13 [72%] of 18 patients). Plausibly, initiating amphotericin B when the patient met criteria for probable IA with a lower Aspergillus burden and illness severity may have been important in producing better survival. Thus, an "intent-to-treat" for IA prompted by the isolation of Aspergillus and a compatible symptom complex reflects a reasonable clinical bias whose purpose is to abort progression to more widespread invasive disease; this is commensurate with published Infectious Diseases Society of America guidelines, which qualified this approach as a category BIII recommendation [33] .
There have been no randomized clinical trials comparing ABLC with amphotericin B in IA. Hiemenz et al. [34] reported a 40% clinical response in patients with IA whose treatment was changed to ABLC because of amphotericin-intolerant refractory disease, compared with a 23% response in a historical amphotericin B cohort. In a study limited to solid-organ transplant recipients, a 47% favorable response was reported from a larger database of 556 patients with mycotic infection enrolled in 3 open-label second-line ABLC studies [35] . Two other commercially available lipid formulations have also shown some benefits for aspergillosis. Amphotericin B cholesteryl sulfate dispersion (Amphotec; ALZA Pharmaceuticals) improved outcome in IA, compared with conventional amphotericin B treatment, although the use of this agent has been hampered by infusion-related toxicities [26] . Treatment with liposomal amphotericin B (AmBisome; Gilead Pharmaceuticals) has shown improved outcome of suspected and documented fungal infection including aspergillosis compared with amphotericin B treatment in 2 randomized trials of neutropenia [36, 37] . Two published prospective trials comparing ABLC with liposomal amphotericin B for neutropenia did not show significant differences in emergent aspergillosis or response rates to proven Aspergillus infection; however, both were not powered to show even modest efficacy differences [38, 39] .
How might lipid-complexed amphotericin B improve the outcome for this highly lethal mycoses? At present, supporting evidence is limited. Containment at the pulmonary phase before hematogenous dissemination can occur is fundamental to achieving favorable responses. Failure to achieve adequate tissue levels of drug has been hypothesized to be an important factor leading to poor outcome [40] . Higher lung concentrations of amphotericin B might play a beneficial role in aborting hematogenous dissemination from the lung. Concentrations of amphotericin B in lung, determined postmortem, were significantly higher among patients receiving ABLC than among those receiving amphotericin B (222 mg/g vs. 13 mg/g) [12] . In a second autopsy study, concentrations of amphotericin B in lung were 17-78 times higher in organ recipients treated with ABLC at 5 mg/kg per day for 3-38 days than in historical controls treated with conventional amphotericin B [41] . ABLC also demonstrated higher lung uptake and lung retention than did amphotericin B or liposomal amphotericin B in a feline study [42] .
Enhanced fungal cytotoxicity may stem from higher affinity of the lipid moiety for fungal cell membrane ergosterol; however, there is only limited proof for this concept [43] [44] [45] . An association between in vitro amphotericin susceptibility of Aspergillus strains to clinical outcome has been shown, but no correlative studies have been conducted with ABLC or other lipid formulations [46] . In vitro testing for ABLC is complicated by the absence of tissue-derived lipases, which enhance the local release of amphotericin B from the lipid complex, and thus may underestimate in vivo ABLC activity [47] .
This study has several important limitations that merit discussion. Undetected differences between the study groups could have accounted for outcome differences. The study encompassed a long time period during which evolving changes in the management of liver transplant recipients could have favored better outcomes during the ABLC period. In this regard, we examined the time delay from diagnosis of IA to therapy, other antifungal therapies (itraconazole and surgical excision), and immunosuppressive strategies. ABLC was initiated slightly earlier than amphotericin B; however, the median time difference was minimal (0.5 days). Combination therapy with oral itraconazole was used more frequently in the ABLC cohort (9 [75%] of 12 patients vs. 8 [28%] of 29 patients); however, mortality rates in the itraconazole-treated subsets were not significantly lower. Two favorable responses to oral itraconazole and ABLC have been reported in patients with IA after liver transplantation, although both culminated in fatal relapses [48] . Concerns about itraconazole include poor serum levels when administered orally to critically ill patients and antagonism with polyenes, on the basis of in vitro studies and animal model experiments [49, 50] .
Recent studies showing that salvage therapy with caspofungin [27] or de novo or salvage therapy with voriconazole [25] produced significant efficacy rates in patients with IA provide the basis for future comparative or combination studies with ABLC.
In summary, we report significantly improved survival rates among critically ill liver transplant recipients treated with ABLC, either as primary or early second-line therapy, compared with the survival rates among those treated with conventional amphotericin B. Consideration should be given for the early firstline use of this agent in suspected or documented IA after liver transplantation in light of the extremely high mortality rates observed with high-dose conventional amphotericin B treatment.
